Diligence memo · auto-generated · as of July 2, 2026

TheoremDx Inc.

TheoremDx Inc. looks over-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

TheoremDx Inc. operates in Biotechnology, based in ST. PAUL.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

TheoremDx Inc. has raised $793K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $793K on 2017-11-02.

Most recent recorded round closed around 2017-11-02.

Valuation (modeled)modeled

Provath models TheoremDx Inc. at approximately $44M (range $423K–$497M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 2.07× the median modeled value of Pre-Seed Biotechnology companies in 2016–2018 (152 peers) — value vs value, same stage and era. Issuer reports no revenue, yet is modeled well above niche peers.

Financing rhythm & timingmixed

Last raise 8.7 yr ago; this sector typically re-raises about every 14 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 15% of Biotechnology peers (4293 compared).

Modeled value ranks above 42% of those peers.

Closest niche peers: New Vital Signs, Inc., Cerebral Magnetics INC, NutriBand Inc., Jivana Biotechnology Inc, AnTolRx, Inc..

Peoplefiled

7 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.